Anti-tumorigenic effects have also been reported where the type 2 diabetes drug, metformin was shown to induce anti-tumor effects through the metabolic reprogramming of CD11b+ myeloid cells, causing them to inhibit osteosarcoma tumor growth [40]. The gene discussed is ITGAM; the disease is type 2 diabetes mellitus.